1 – 100 of 110
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Eight Misconceptions about Prostate-Specific Antigen
(
- Contribution to journal › Article
-
Mark
Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GÖTEBORG-2 Prostate Cancer Screening Trial
2024) In European Urology(
- Contribution to journal › Article
-
Mark
Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the Norwegian Prostate Cancer Consortium
(
- Contribution to journal › Article
- 2023
-
Mark
Provider Perceptions of an Electronic Health Record Prostate Cancer Screening Tool
(
- Contribution to journal › Article
-
Mark
Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality : 24-Year Follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial
(
- Contribution to journal › Article
-
Mark
A Provider-Facing Decision Support Tool for Prostate Cancer Screening in Primary Care : A Pilot Study
(
- Contribution to journal › Article
-
Mark
Pain as bad as you can imagine or extremely severe pain? A randomized controlled trial comparing two pain scale anchors
(
- Contribution to journal › Article
-
Mark
Predictive value of kallikrein forms and β-microseminoprotein in blood from patients with evidence of detectable levels of PSA after radical prostatectomy
(
- Contribution to journal › Article
- 2022
-
Mark
How Should Molecular Markers and Magnetic Resonance Imaging Be Used in the Early Detection of Prostate Cancer?
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Predicting Grade group 2 or higher cancer at prostate biopsy by 4Kscore in blood and uCaP microRNA model in urine
(
- Contribution to journal › Article
-
Mark
Prostate cancer polygenic risk score and prediction of lethal prostate cancer
(
- Contribution to journal › Article
-
Mark
Independent validation of a pre-specified four-kallikrein marker model for prediction of adverse pathology and biochemical recurrence
(
- Contribution to journal › Article
- 2021
-
Mark
Individual Patient Data Meta-analysis of Discrimination of the Four Kallikrein Panel Associated With the Inclusion of Prostate Volume
(
- Contribution to journal › Article
-
Mark
Prospective validation of microseminoprotein-β added to the 4Kscore in predicting high-grade prostate cancer in an international multicentre cohort
(
- Contribution to journal › Article
- 2020
-
Mark
Prespecified 4-Kallikrein Marker Model at Age 50 or 60 for Early Detection of Lethal Prostate Cancer in a Large Population Based Cohort of Asymptomatic Men Followed for 20 Years
(
- Contribution to journal › Article
-
Mark
Reply by Authors
(
- Contribution to journal › Article
-
Mark
A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy
(
- Contribution to journal › Article
-
Mark
The Four-Kallikrein Panel Is Effective in Identifying Aggressive Prostate Cancer in a Multiethnic Population
2020) In Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 29(7). p.1381-1388(
- Contribution to journal › Article
- 2019
-
Mark
Reply to Kathryn L. Penney, Massimo Loda, and Meir J. Stampfer's Letter to the Editor re : Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Eur Urol 2018;73:961–7
(
- Contribution to journal › Letter
-
Mark
Kallikrein markers performance in pretreatment blood to predict early prostate cancer recurrence and metastasis after radical prostatectomy among very high-risk men
2019) In Prostate(
- Contribution to journal › Article
-
Mark
A Four-kallikrein Panel and β-Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy : An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer
(
- Contribution to journal › Article
-
Mark
Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men
(
- Contribution to journal › Article
- 2018
-
Mark
Re : Tobias Nordström, Andrew Vickers, Melissa Assel, Hans Lilja, Henrik Grönberg, Martin Eklund. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. Eur Urol 2015;68:139–46
(
- Contribution to journal › Letter
-
Mark
Association Between Lead Time and Prostate Cancer Grade : Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening
(
- Contribution to journal › Article
-
Mark
Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men
(
- Contribution to journal › Article
-
Mark
Long-term prediction of prostate cancer diagnosis and death using PSA and obesity related anthropometrics at early middle age : Data from the malmö preventive project
(
- Contribution to journal › Article
-
Mark
Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model : An Individual Patient Data Meta-Analysis
(
- Contribution to journal › Article
- 2017
-
Mark
Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study
(
- Contribution to journal › Article
-
Mark
Prostate Specific Antigen and Prostate Cancer in Chinese Men Undergoing Initial Prostate Biopsies Compared with Western Cohorts
(
- Contribution to journal › Article
-
Mark
Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone : Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above
(
- Contribution to journal › Article
- 2016
-
Mark
Beyond prostate-specific antigen : Utilizing novel strategies to screen men for prostate cancer
(
- Contribution to journal › Scientific review
-
Mark
Reply to Re : The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening
(
- Contribution to journal › Letter
-
Mark
The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening
(
- Contribution to journal › Article
-
Mark
Author Reply
(
- Contribution to journal › Letter
-
Mark
Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel
2016) In Journal of Urology(
- Contribution to journal › Article
-
Mark
Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice : A microsimulation screening analysis
(
- Contribution to journal › Article
- 2015
-
Mark
Clinical Consultation Guide : How to Optimize the Use of Prostate-specific Antigen in the Current Era
(
- Contribution to journal › Article
-
Mark
Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.
(
- Contribution to journal › Article
-
Mark
A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort.
2015) In European Urology(
- Contribution to journal › Article
-
Mark
Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.
(
- Contribution to journal › Article
-
Mark
Predicting High-Grade Cancer at Ten-Core Prostate Biopsy Using Four Kallikrein Markers Measured in Blood in the ProtecT Study.
(
- Contribution to journal › Article
-
Mark
Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death.
(
- Contribution to journal › Article
- 2014
-
Mark
It Ain't what you do, it's the way you do it : Five golden rules for transforming prostate-specific antigen screening
(
- Contribution to journal › Article
-
Mark
Prostate cancer mortality in areas with high and low prostate cancer incidence.
(
- Contribution to journal › Article
-
Mark
Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening : Population based cohort study
(
- Contribution to journal › Article
-
Mark
Cancer-associated Changes in the Expression of TMPRSS2-ERG, PCA3, and SPINK1 in Histologically Benign Tissue From Cancerous vs Noncancerous Prostatectomy Specimens.
(
- Contribution to journal › Article
-
Mark
The Added Value of Percentage of Free to Total Prostate-specific Antigen, PCA3, and a Kallikrein Panel to the ERSPC Risk Calculator for Prostate Cancer in Prescreened Men.
(
- Contribution to journal › Article
-
Mark
Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen
(
- Contribution to journal › Article
-
Mark
Inhibition of Circulating Dipeptidyl Peptidase 4 Activity in Patients with Metastatic Prostate Cancer
(
- Contribution to journal › Article
-
Mark
Evaluating the Prostate Cancer Prevention Trial High Grade prostate cancer risk calculator in 10 international biopsy cohorts : Results from the prostate biopsy collaborative group
(
- Contribution to journal › Article
-
Mark
Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study.
2014) In European Urology(
- Contribution to journal › Article
- 2013
-
Mark
A Systematic Review of the Volume-Outcome Relationship for Radical Prostatectomy
(
- Contribution to journal › Scientific review
-
Mark
Association of cancer with moderately impaired renal function at baseline in a large, representative, population-based cohort followed for up to 30 years.
(
- Contribution to journal › Article
-
Mark
Predictive Value of Four Kallikrein Markers for Pathologically Insignificant Compared With Aggressive Prostate Cancer in Radical Prostatectomy Specimens: Results From the European Randomized Study of Screening for Prostate Cancer Section Rotterdam
(
- Contribution to journal › Article
-
Mark
Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk?
(
- Contribution to journal › Article
-
Mark
Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study
(
- Contribution to journal › Article
-
Mark
Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men : The PROBASE trial
(
- Contribution to journal › Article
- 2012
-
Mark
PSA is Dead, Long Live PSA
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Predicting prostate cancer many years before diagnosis : How and why?
(
- Contribution to journal › Article
-
Mark
We need a better marker for prostate cancer. How about renaming PSA?
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Urological cancer : Time for another rethink on prostate cancer screening
(
- Contribution to journal › Article
-
Mark
Screening for Prostate Cancer: Early Detection or Overdetection?
(
- Contribution to journal › Scientific review
-
Mark
Screening for prostate cancer : To the editor
(
- Contribution to journal › Letter
-
Mark
Prostate Cancer Screening: Facts, Statistics, and Interpretation in Response to the US Preventive Services Task Force Review
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses
(
- Contribution to journal › Article
-
Mark
Evaluation of Multiple Risk-Associated Single Nucleotide Polymorphisms Versus Prostate-Specific Antigen at Baseline to Predict Prostate Cancer in Unscreened Men
(
- Contribution to journal › Article
-
Mark
Levels of Beta-Microseminoprotein in Blood and Risk of Prostate Cancer in Multiple Populations.
2012) In Journal of the National Cancer Institute(
- Contribution to journal › Article
-
Mark
Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators : Results from the prostate biopsy collaborative group
(
- Contribution to journal › Article
-
Mark
Evaluating the PCPT risk calculator in ten international biopsy cohorts : Results from the Prostate Biopsy Collaborative Group
(
- Contribution to journal › Article
- 2011
-
Mark
Prostate-specific Antigen/Solvent Interaction Analysis: A Preliminary Evaluation of a New Assay Concept for Detecting Prostate Cancer Using Urinary Samples EDITORIAL COMMENT
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection
(
- Contribution to journal › Article
-
Mark
Tumor markers in prostate cancer I: Blood-based markers
(
- Contribution to journal › Scientific review
-
Mark
Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.
(
- Contribution to journal › Article
-
Mark
A Panel of Kallikrein Marker Predicts Prostate Cancer in a Large, Population-Based Cohort Followed for 15 Years without Screening
(
- Contribution to journal › Article
-
Mark
Prediction of Significant Prostate Cancer Diagnosed 20 to 30 Years Later With a Single Measure of Prostate-Specific Antigen at or Before Age 50
(
- Contribution to journal › Article
-
Mark
Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively
(
- Contribution to journal › Article
- 2010
-
Mark
Finasteride to prevent prostate cancer : Should all men or only a high-risk subgroup be treated?
(
- Contribution to journal › Article
-
Mark
Empirical Estimates of the Lead Time Distribution for Prostate Cancer Based on Two Independent Representative Cohorts of Men Not Subject to Prostate-Specific Antigen Screening.
2010) In Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology May 4. p.1201-1207(
- Contribution to journal › Article
-
Mark
A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up : An independent validation study from the European Randomized Study of Prostate Cancer screening, France
(
- Contribution to journal › Article
-
Mark
Reducing Unnecessary Biopsy During Prostate Cancer Screening Using a Four-Kallikrein Panel: An Independent Replication.
(
- Contribution to journal › Article
-
Mark
Impact of Recent Screening on Predicting the Outcome of Prostate Cancer Biopsy in Men With Elevated Prostate-Specific Antigen Data From the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden
(
- Contribution to journal › Article
-
Mark
A Four-Kallikrein Panel Predicts Prostate Cancer in Men with Recent Screening: Data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam
(
- Contribution to journal › Article
-
Mark
Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer : Case-control study
(
- Contribution to journal › Article
-
Mark
Prostate Specific Antigen Velocity Does Not Aid Prostate Cancer Detection in Men With Prior Negative Biopsy
(
- Contribution to journal › Article
-
Mark
Blood Biomarker Levels to Aid Discovery of Cancer-Related Single-Nucleotide Polymorphisms: Kallikreins and Prostate Cancer.
(
- Contribution to journal › Article
-
Mark
Susceptibility Loci Associated with Prostate Cancer Progression and Mortality
(
- Contribution to journal › Article
-
Mark
The relationship between prostate-specific antigen and prostate cancer risk : The prostate biopsy collaborative group
(
- Contribution to journal › Article
-
Mark
The Learning Curve for Laparoscopic Radical Prostatectomy: An International Multicenter Study
(
- Contribution to journal › Article
- 2009
-
Mark
Prostate cancer : Estimating the benefits of PSA screening
(
- Contribution to journal › Article
-
Mark
Cutpoints in clinical chemistry : Time for fundamental reassessment
(
- Contribution to journal › Article
-
Mark
In reply
(
- Contribution to journal › Letter
-
Mark
Systematic review of Pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer
(
- Contribution to journal › Article
-
Mark
THE CONTINUING ROLE OF PROSTATE-SPECIFIC ANTIGEN AS A MARKER FOR LOCALIZED PROSTATE CANCER: 'DO NOT THROW THE BABY OUT WITH THE BATH WATER'
(
- Contribution to journal › Article
-
Mark
Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy
(
- Contribution to journal › Article
-
Mark
Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy
(
- Contribution to journal › Article
-
Mark
Prostate-Specific Antigen Velocity for Early Detection of Prostate Cancer: Result from a Large, Representative, Population-based Cohort
(
- Contribution to journal › Article
- 2008
-
Mark
Five genetic variants associated with prostate cancer [9]
(
- Contribution to journal › Letter
-
Mark
Prostate-specific antigen and prostate cancer: prediction, detection and monitoring
(
- Contribution to journal › Scientific review
-
Mark
Systematic review of statistical methods used in molecular marker studies in cancer
(
- Contribution to journal › Article
-
Mark
A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden
(
- Contribution to journal › Article